Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720453 | 0.86 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL719038 | 0.82 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL23400080 | 0.79 | MIF (0.44) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL720432 | 0.78 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL719452 | 0.78 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL717913 | 0.76 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL719988 | 0.75 | MEN1 (0.56) | L3MBTL1ALDH1A1KMT2AMEN1CA12 | |
| SCHEMBL23142702 | 0.73 | MAPT (0.40) | L3MBTL1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4296566 | 0.72 | NPSR1 (0.61) | ALDH1A1CA12CA9MAPT | |
| SCHEMBL6052367 | 0.71 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KMT2AMEN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | L3MBTL1 4088/4885ALDH1A1 504/4885KMT2A 1298/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | L3MBTL1 4088/4885ALDH1A1 504/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.